CD70 and renal cell carcinoma: In preclinical RCC animal and cell models, CD70 CAR‐T cells incorporating nanobodies demonstrated enhanced cytokine production and greater antitumour efficacy relative to scFv‐based CAR‐T cells,92 suggesting that nanobody‐based CAR constructs hold potential for improving CD70‐directed CAR‐T therapies against solid tumours and merit further clinical evaluation.92